Mechanism of CD38 Via NAD in the Development of Non-alcoholic Fatty Liver Disease

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2023 Feb 16

PMID 36794157

Authors

Min Dong

Shuo Wang

Zuowei Pei

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease globally, and it can proceed to cirrhosis and hepatocellular carcinoma, as well as cardiovascular disease, chronic renal disease, and other complications, resulting in a massive economic burden. At the moment, nicotinamide adenine dinucleotide (NAD) is thought to be a possible treatment target for NAFLD, besides Cluster of differentiation 38(CD38) is the primary NAD degrading enzyme in mammals and may play a role in the pathophysiology of NAFLD. For example, CD38 regulates Sirtuin 1 activity and hence affects inflammatory responses. CD38 inhibitors enhance glucose intolerance and insulin resistance in mice and lipid accumulation in the liver is greatly decreased in CD38-deficient mice. This review describes the role of CD38 in the development of NAFLD in terms of Macrophage-1, insulin resistance, and abnormal lipid accumulation in order to offer recommendations for future NAFLD pharmacological trials.

Citing Articles

CD38 modulates cytokine secretion by NK cells through the Sirt1/NF-κB pathway, suppressing immune surveillance in colorectal cancer.

Wang X, Song X, Fang K, Chang X Sci Rep. 2024; 14(1):28702.

PMID: 39562615 PMC: 11577103. DOI: 10.1038/s41598-024-79008-8.

References

Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z . Metabolic Changes of Hepatocytes in NAFLD. Front Physiol. 2021; 12:710420. PMC: 8437340. DOI: 10.3389/fphys.2021.710420. View

Okamoto H, Takasawa S . Okamoto model for necrosis and its expansions, CD38-cyclic ADP-ribose signal system for intracellular Ca mobilization and Reg (Regenerating gene protein)-Reg receptor system for cell regeneration. Proc Jpn Acad Ser B Phys Biol Sci. 2021; 97(8):423-461. PMC: 8553518. DOI: 10.2183/pjab.97.022. View

Yoshizaki T, Schenk S, Imamura T, Babendure J, Sonoda N, Bae E . SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab. 2009; 298(3):E419-28. PMC: 2838524. DOI: 10.1152/ajpendo.00417.2009. View

Mendez-Frausto G, Romero-Aguilera G, Sanchez-Gutierrez R, Garcia-Jacobo R, Lara-Ramirez E, Uresti-Rivera E . B regulatory cells associated with changes in biochemical and inflammatory parameters in normal-glycemic individuals, pre-diabetes and T2DM patients. Diabetes Res Clin Pract. 2021; 173:108692. DOI: 10.1016/j.diabres.2021.108692. View

Chini C, Peclat T, Warner G, Kashyap S, Espindola-Netto J, de Oliveira G . CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD and NMN levels. Nat Metab. 2020; 2(11):1284-1304. PMC: 8752031. DOI: 10.1038/s42255-020-00298-z. View

Alexander M, Loomis A, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D . Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019; 17(1):95. PMC: 6526616. DOI: 10.1186/s12916-019-1321-x. View

Braidy N, Berg J, Clement J, Khorshidi F, Poljak A, Jayasena T . Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. Antioxid Redox Signal. 2018; 30(2):251-294. PMC: 6277084. DOI: 10.1089/ars.2017.7269. View

Covarrubias A, Perrone R, Grozio A, Verdin E . NAD metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2020; 22(2):119-141. PMC: 7963035. DOI: 10.1038/s41580-020-00313-x. View

Chini C, Tarrago M, Chini E . NAD and the aging process: Role in life, death and everything in between. Mol Cell Endocrinol. 2016; 455:62-74. PMC: 5419884. DOI: 10.1016/j.mce.2016.11.003. View

10.

Camacho-Pereira J, Tarrago M, Chini C, Nin V, Escande C, Warner G . CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016; 23(6):1127-1139. PMC: 4911708. DOI: 10.1016/j.cmet.2016.05.006. View

11.

Wang L, Miao L, Wang X, Huang C, Qian Y, Huang X . CD38 deficiency suppresses adipogenesis and lipogenesis in adipose tissues through activating Sirt1/PPARγ signaling pathway. J Cell Mol Med. 2017; 22(1):101-110. PMC: 5742727. DOI: 10.1111/jcmm.13297. View

12.

Escande C, Nin V, Price N, Capellini V, Gomes A, Barbosa M . Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2012; 62(4):1084-93. PMC: 3609577. DOI: 10.2337/db12-1139. View

13.

Boslett J, Reddy N, Alzarie Y, Zweier J . Inhibition of CD38 with the Thiazoloquin(az)olin(on)e 78c Protects the Heart against Postischemic Injury. J Pharmacol Exp Ther. 2019; 369(1):55-64. PMC: 6413770. DOI: 10.1124/jpet.118.254557. View

14.

Kleiner D, Brunt E, Wilson L, Behling C, Guy C, Contos M . Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019; 2(10):e1912565. PMC: 6784786. DOI: 10.1001/jamanetworkopen.2019.12565. View

15.

Barbosa M, Soares S, Novak C, Sinclair D, Levine J, Aksoy P . The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 2007; 21(13):3629-39. DOI: 10.1096/fj.07-8290com. View

16.

Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh V, Ferrero E . CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom. 2013; 84(4):207-17. DOI: 10.1002/cyto.b.21092. View

17.

Wang L, Huang C, Xiao Y, Guan X, Wang X, Cao Q . CD38 Deficiency Protects Heart from High Fat Diet-Induced Oxidative Stress Via Activating Sirt3/FOXO3 Pathway. Cell Physiol Biochem. 2018; 48(6):2350-2363. DOI: 10.1159/000492651. View

18.

Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein A, Ortolan E . Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008; 88(3):841-86. DOI: 10.1152/physrev.00035.2007. View

19.

Astigiano C, Benzi A, Laugieri M, Piacente F, Sturla L, Guida L . Paracrine ADP Ribosyl Cyclase-Mediated Regulation of Biological Processes. Cells. 2022; 11(17). PMC: 9454491. DOI: 10.3390/cells11172637. View

20.

Bock K . Aryl hydrocarbon receptor (AHR) functions: Balancing opposing processes including inflammatory reactions. Biochem Pharmacol. 2020; 178:114093. DOI: 10.1016/j.bcp.2020.114093. View